Clinicians and researchers at National Jewish Health have studied COVID vaccine effectiveness in patients with underlying lung conditions such as asthma, chronic obstructive pulmonary disease (COPD) and interstitial lung disease (ILD). Findings show that nearly half of respiratory patients have lower vaccine-specific antibody, B cell, and T cell responses than healthy individuals. Decreased immunity to the vaccine suggests that patients with underlying lung conditions may be less protected against COVID-19. Understanding why they aren’t responding can give doctors a chance to treat patients differently.
New study examines COVID vaccine protection for patients with lung conditions
Clinicians and researchers at National Jewish Health have studied COVID vaccine effectiveness in patients with underlying lung conditions such as asthma, chronic obstructive pulmonary disease (COPD) and interstitial lung disease (ILD). Findings show that nearly half of respiratory patients have lower vaccine-specific antibody, B cell, and T cell responses than healthy individuals. Decreased immunity to the vaccine suggests that patients with underlying lung conditions may be less protected against COVID-19. Understanding why they aren't responding can give doctors a chance to treat patients differently.